NVDA
NVIDIA
-- 134.250 AVGO
Broadcom
-- 224.800 TSLA
Tesla
-- 436.230 PLTR
Palantir
-- 76.070 AMD
Advanced Micro Devices
-- 126.910 
NEWS
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics (Nasdaq: INTS) has announced the dosing of the first U.S. patient in its global Phase 3 study (INVINCIBLE-3) for metastatic soft tissue sarcoma using its lead product candidate, INT230-6, as a monotherapy. This trial will compare INT230-6 against standard-of-care chemotherapy in second and third-line treatments. The study will enroll approximately 333 patients across multiple countries. Phase 1/2 trials showed promising tumor-killing and immune-activating properties, with a median overall survival of 21.3 months. Regulatory filings for trial initiation have been submitted in Canada and Europe.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment